Sanofi said it agreed to buy U.K. vaccine developer Vicebio for up to $1.6 billion, adding vaccine candidates for respiratory syncytial virus and human metapneumovirus to its pipeline.

Sanofi agreed to buy UK vaccine developer Vicebio Ltd. for as much as $1.6 billion, as it seeks to expand in respiratory ...

Top experts from Amgen, CBIZ & Intrepid discuss 2025 trends in healthcare, biotech, and life sciences. Explore key insights ...

Investors should consider ICICI Pru’s Pharma Healthcare & Diagnostics Fund for exposure to healthcare amid tariff volatility.

New appointments to the leadership team also include Stefan Larson as Chair of the Board of Directors and Ingmar Bruns as a ...

As of March 2025, BC Investments IV held an 8.68% stake in Emcure. American investment giant Carlyle Group is planning to sell up to a 10% stake in Piramal Pharma via block trades, which could earn ...

TORONTO, July 02, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company focused on the development and ...

BridgeBio secures $300 million from royalty financing, enhancing its financial position for Attruby® launch and pipeline development.

BridgeBio Pharma will host a webinar on limb-girdle muscular dystrophy with Dr. Matthew Wicklund on July 11, 2025.